These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29428637)

  • 1. Re: Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma: L. M. Krabbe, B. Heitplatz, S. Preuss, R. C. Hutchinson, S. L. Woldu, N. Singla, M. Boegemann, C. G. Wood, J. A. Karam, A. Z. Weizer, J. D. Raman, M. Remzi, N. Rioux-Leclercq, A. Haitel, L. M. Rapoport, P. V. Glybochko, M. Roscigno, C. Bolenz, K. Bensalah, A. I. Sagalowsky, S. F. Shariat, Y. Lotan, E. Xylinas and V. Margulis J Urol 2017;198:1253-1262.
    Miyama Y; Miyakawa J; Morikawa T
    J Urol; 2018 May; 199(5):1353-1354. PubMed ID: 29428637
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy: R. D. da Silva, E. Xylinas, L. Kluth, J. J. Crivelli, J. Chrystal, D. Chade, G. B. Guglielmetti, A. Pycha, Y. Lotan, P. I. Karakiewicz, M. Sun, H. Fajkovic, M. Zerbib, D. S. Scherr and S. F. Shariat J Urol 2013;190:487-492.
    Ozgur BC; Sarici H; Yuceturk CN
    J Urol; 2014 Aug; 192(2):618-9. PubMed ID: 24792987
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy: R. D. Da silva, e. Xylinas, L. Kluth, j. J. Crivelli, j. Chrystal, d. Chade, g. B. Guglielmetti, a. Pycha, y. Lotan, p. I. Karakiewicz, m. Sun, h. Fajkovic, m. Zerbib, d. S. Scherr and s. F. Shariat j urol 2013; 190: 487-492.
    Atmaca AF
    J Urol; 2014 Jan; 191(1):273. PubMed ID: 24139793
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder: E. Xylinas, E. K. Cha, F. Khani, L. A. Kluth, M. Rieken, B. G. Volkmer, R. Hautmann, R. Küfer, Y.-T. Chen, M. Zerbib, M. A. Rubin, D. S. Scherr, S. F. Shariat and B. D. Robinson J Urol 2014;191:830-841.
    Szarvas T; Rübben H; Reis H
    J Urol; 2014 Aug; 192(2):617-8. PubMed ID: 24792989
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications: S. A. M. Wankowicz, L. Werner, A. Orsola, J. Novak, M. Bowden, T. K. Choueiri, I. de Torres, J. Morote, G. J. Freeman, S. Signoretti and J. Bellmunt J Urol 2017;198:817-823.
    Rouanne M; Lebret T; Radulescu C; Adam J
    J Urol; 2018 Mar; 199(3):854-856. PubMed ID: 29179001
    [No Abstract]   [Full Text] [Related]  

  • 6. [Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma].
    Campedel L; Seisen T; Cussenot O; Comperat E; Varinot J; Rouprêt M; Cancel-Tassin G
    Prog Urol; 2018 Dec; 28(16):900-905. PubMed ID: 30219646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary on "Impact of statin use on oncologic outcomes in patients with urothelial carcinoma ofthe bladder treated with radical cystectomy." da Silva RD, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Chade D, Guglielmetti GB, Pycha A, Lotan Y, Karakiewicz PI, Sun M, Fajkovic H, Zerbib M, Scherr DS, Shariat SF, Department of Urology and Division of Medical Oncology, Weill Cornell Medical College, New York - Presbyterian Hospital, New York, New York 10065, USA.: J Urol 2013; 190(2):487-92. doi:10.1016/j.juro.2013.02.003. [Epub 2013 Feb 8].
    Kamat A
    Urol Oncol; 2015 Jan; 33(1):47-48. PubMed ID: 25528639
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus: E. J. Abel, T. A. Masterson, J. A. Karam, V. A. Master, V. Margulis, R. Hutchinson, C. A. Lorentz, E. Bloom, T. M. Bauman, C. G. Wood and M. L. Blute, Jr. J Urol 2017;198:810-816.
    Gu L; Ma X; Zhang X
    J Urol; 2018 Mar; 199(3):853-854. PubMed ID: 29178998
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: R. S. Liao, M. Gupta, Z. R. Schwen, H. D. Patel, M. Kates, M. H. Johnson, N. M. Hahn, D. McConkey, T. J. Bivalacqua and P. M. Pierorazio J Urol 2018;200:68-73.
    Xue W; Yang L; Wei Q
    J Urol; 2018 Dec; 200(6):1378-1379. PubMed ID: 30172893
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy: W. C. Duivenvoorden, S. Daneshmand, D. Canter, Y. Lotan, P. C. Black, H. Abdi, B. W. van Rhijn, E. E. Fransen van de Putte, P. Zareba, I. Koskinen, W. Kassouf, S. L. Traboulsi, J. E. Kukreja, P. J. Boström, B. Shayegan and J. H. Pinthus J Urol 2016;196:1627-1633.
    Ramos JD; Yu EY
    J Urol; 2017 May; 197(5):1360-1362. PubMed ID: 28183523
    [No Abstract]   [Full Text] [Related]  

  • 11. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
    Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
    Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma: B. A. Gayed, C. Seideman and y. Lotan J Urol 2013;190:1181-1186.
    Tian Y; Wazir R; Wang K
    J Urol; 2014 May; 191(5):1472. PubMed ID: 24513143
    [No Abstract]   [Full Text] [Related]  

  • 14. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
    de Jong JJ; Stoop H; Nieboer D; Boormans JL; van Leenders GJLH
    Histopathology; 2018 Dec; 73(6):983-989. PubMed ID: 30003574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019;75:538-40.
    Gevaert T; Eckstein M; Montironi R; Lopez-Beltran A
    Eur Urol; 2019 Jun; 75(6):e162-e163. PubMed ID: 30712970
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Stenting Prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence: B. Kiss, M. A. Furrer, P. Y. Wuethrich, F. C. Burkhard, G. N. Thalmann and B. Roth J Urol 2017;198:1263-1268.
    Zargar-Shoshtari K; Sexton WJ
    J Urol; 2018 Aug; 200(2):457-458. PubMed ID: 29772193
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Stenting prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence: B. Kiss, M. A. Furrer, P. Y. Wuethrich, F. C. Burkhard, G. N. Thalmann and B. Roth J Urol 2017;198:1263-1268.
    Sood A; Abdollah F; Cole D; Alanee S
    J Urol; 2018 Apr; 199(4):1069-1070. PubMed ID: 29305838
    [No Abstract]   [Full Text] [Related]  

  • 20. Commentary on "Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition." Ros MM, Bueno de Mesquita HB, Kampman E, Aben KK, Büchner FL, Jansen EH, van Gils CH, Egevad L, Overvad K, Tjønneland A, Roswall N, Boutron Ruault MC, Kvaskoff M, Perquier F, Kaaks R, Chang Claude J, Weikert S, Boeing H, Trichopoulou A, Lagiou P, Dilis V, Palli D, Pala V, Sacerdote C, Tumino R, Panico S, Peeters PH, Gram IT, Skeie G, Huerta JM, Barricarte A, Quirós JR, Sánchez MJ, Buckland G, Larrañaga N, Ehrnström R, Wallström P, Ljungberg B, Hallmans G, Key TJ, Allen NE, Khaw KT, Wareham N, Brennan P, Riboli E, Kiemeney LA, National Institute for Public Health and the Environment, Bilthoven, Netherlands: Am J Clin Nutr 2012;96(4):902-10 [Epub 2012 Sep 5].
    See WA
    Urol Oncol; 2013 Jul; 31(5):714-5. PubMed ID: 23796198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.